# Kellie N. Smith

Source: https://onco.cc/people/kellie-smith/  
OnCo record `kellie-smith` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Developed the MANAFEST assay to track the tumour-specific T cells that immunotherapy awakens.

## Summary

Kellie N. Smith is Associate Professor of Oncology at the Bloomberg~Kimmel Institute, Johns Hopkins Hospital and Sidney Kimmel Comprehensive Cancer Center. She is a T-cell immunologist known for developing the MANAFEST assay, which detects and tracks the mutation-associated neoantigen-specific T cells that immunotherapy awakens. Her selected paper describes MANAFEST as a functional assay for neoantigen-specific T cells. She now applies these assays to neoadjuvant immunotherapy trials, with relevance to checkpoint inhibitors and personalised neoantigen vaccines.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Associate Professor of Oncology; Bloomberg~Kimmel Institute
- Specialisms: T-cell immunology; Neoantigen-specific T cells; MANAFEST assay

## Sources

- Hopkins profile: https://www.hopkinsmedicine.org/profiles/details/kellie-smith
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Smith%20KN%5BAuthor%5D

## Connected records

- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Personalised neoantigen (mRNA) vaccines](https://onco.cc/technologies/neoantigen-mrna-vaccine/)
- institutions: [Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center](https://onco.cc/institutions/johns-hopkins/)
- terms: [Neoantigen](https://onco.cc/terms/neoantigen/)
- journals: [Cancer Immunology Research](https://onco.cc/journals/cancer-immunology-research/)

---
JSON: https://onco.cc/api/v1/entities/kellie-smith.json